GLP-1 Vision Loss Lawsuit: Frequently Asked Questions

The GLP-1 vision loss lawsuit (MDL 3163) involves claims that GLP-1 receptor agonist drugs such as Ozempic, Wegovy, Mounjaro, Trulicity, and Zepbound significantly increase the risk of NAION — a sudden, often permanent form of vision loss. A Harvard study published in JAMA Ophthalmology found a 4x to 7.6x elevated NAION risk in GLP-1 users. Manufacturers allegedly failed to update their labels to warn patients and prescribers.

MDL 3163 is the federal multidistrict litigation consolidating GLP-1 NAION lawsuits before Judge Karen Marston in the Eastern District of Pennsylvania. The MDL leadership was appointed in March 2026. This is one of the newest major pharmaceutical MDLs in the US — an early-stage opportunity for claimants.

The two main defendants are Novo Nordisk (Ozempic, Wegovy, Rybelsus) and Eli Lilly (Mounjaro, Trulicity, Zepbound). Both are named in product liability claims alleging failure to warn, negligence, and design defect. Notably, Novo Nordisk has not updated its US labels to warn of NAION risk despite the Harvard study findings.

No. As of March 2026, there is no recall of Ozempic, Wegovy, Mounjaro, or other GLP-1 drugs for NAION concerns. The lawsuits proceed as product liability claims alleging failure to warn. See our GLP-1 recall page for more information.

A July 2024 study by researchers at Harvard's Mass Eye and Ear hospital (published in JAMA Ophthalmology) analyzed 16,827 patients and found semaglutide users had 4.28x higher odds of NAION (diabetes patients) and 7.64x higher odds (obesity patients) compared to those on other medications for the same conditions. The researchers explicitly called for NAION to be added to GLP-1 drug labels.

You may be eligible if: (1) you were prescribed Ozempic, Wegovy, Rybelsus, Mounjaro, Trulicity, or Zepbound; (2) you were diagnosed with NAION by an ophthalmologist; (3) your NAION developed during or after GLP-1 use; and (4) you are within your state's statute of limitations. Use our eligibility checker for a personalized assessment.

NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) is a sudden disruption of blood flow to the optic nerve, causing rapid vision loss — often upon waking, without pain. If you experienced sudden vision loss in one eye while taking a GLP-1 drug, see an ophthalmologist immediately. A diagnosis requires visual field testing and an eye examination. Learn more on our NAION information page.

Key documents include: pharmacy records showing GLP-1 prescription history, ophthalmology records documenting NAION diagnosis, visual field test results and OCT scans, records from your prescribing physician, and insurance EOB records. Start gathering these now — records can be harder to obtain over time.

Yes. Even partial or temporary NAION can support a claim. The severity of your vision loss affects case value but not necessarily eligibility. Speak with an attorney about your specific situation.

Yes. Every state has a statute of limitations — typically 2–3 years from the date of NAION diagnosis or from when you discovered the drug connection. See our state-by-state deadline guide.

Pharmaceutical MDLs typically resolve in 3–7 years from formation. MDL 3163 was formed in March 2026. Bellwether trials are likely 2–3 years away (2028). Global settlement discussions may follow successful trial outcomes. This is a long-term process.

An MDL is not a class action. In an MDL, each plaintiff has their own individual case with their own potential recovery based on their specific injuries. Class actions result in uniform payouts. MDLs are better for mass tort injury cases where harm varies significantly between individuals.

No settlements have been reached in MDL 3163. Value depends on vision loss severity, impact on employment/daily life, medical costs, and age at injury. Cases with bilateral vision loss or complete blindness are expected to carry the highest values. See our settlement factors guide.

Mass tort attorneys work on contingency — no upfront fees. You pay nothing unless you win or settle. Attorney fees are typically a percentage of your recovery (often 33–40%), which is spelled out in your retainer agreement.

Most MDL cases resolve through settlement without trial. If your case goes to trial, it may be in the Eastern District of Pennsylvania (where the MDL is located) or remanded to your home district. Your attorney will guide you through any required appearances.